AMG 609

AMG 609 is a small interfering RNA (siRNA) drug candidate developed by Amgen for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It selectively targets a variant allele of patatin-like phospholipase domain-containing protein 3 (PNPLA3), specifically the I148M variant, which is strongly associated with fatty liver disease. The mechanism of action involves inhibition/modulation of PNPLA3 via RNA interference, aiming to reduce hepatic fat accumulation and inflammation. AMG 609 was administered subcutaneously in clinical trials but development has been discontinued following completion of Phase I studies[1][2][3][4][5].